European Journal of Epidemiology

, Volume 23, Issue 5, pp 355–362 | Cite as

Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case–control study

  • Loredana Covolo
  • Donatella Placidi
  • Umberto Gelatti
  • Angela Carta
  • Antonio Scotto Di Carlo
  • Paolo Lodetti
  • Antonio Piccichè
  • Grazia Orizio
  • Marcello Campagna
  • Cecilia Arici
  • Stefano Porru


The aim of the study was to investigate NAT1, NAT2, GSTM1, GSTT1, GSTP1, SULT1A1, XRCC1, XRCC3 and XPD genetic polymorphisms, coffee consumption and risk of bladder cancer (BC) through a hospital-based case–control study. The study population included 197 incident BC cases and 211 controls. The association between genetic polymorphisms, coffee drinking and BC risk was assessed by logistic regression taking into account age, education, tobacco smoking and occupational exposures to polycyclic aromatic hydrocarbons and aromatic amines. No association was found between the genetic polymorphisms investigated and BC risk according to coffee consumption apart of a significant increased BC risk among GSTP1 105-114 Val carriers heavy coffee drinkers (>3 cups/day) (OR 3.18, 95%CI 1.06–9.55). In conclusion our findings suggest a very limited role, if any, of genetic polymorphisms investigated in modulating the BC risk in coffee drinkers.


Bladder cancer Coffee consumption Genetic polymorphisms 



Aromatic amines


Bladder cancer


Confidence interval


Glutathione S-transferases


Hardy–Weinberg equilibrium




Odds ratio


Polycyclic aromatic hydrocarbons


Sulfotransferase 1A1


Xeroderma pigmentosum complementation group


X-ray repair cross-complementing


  1. 1.
    Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol. 2004;22:86–92.PubMedGoogle Scholar
  2. 2.
    AIRT Working Group. I tumori in Italia—rapporto 2006. Incidenza, mortalità e stime. Epidemiol Prev. 2006;30:1–141.Google Scholar
  3. 3.
    Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol. 2006;3:327–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Kogevinas M, Trichopoulos D. Urinary bladder cancer. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology. New York: Oxford University Press; 2002. p. 446–66.Google Scholar
  5. 5.
    International Agency for Research on Cancer (IARC). Coffee, tea, mate, methylxanthines and methylglyoxal. Lyon: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; 1991.Google Scholar
  6. 6.
    Geoffroy-Perez B, Cordier S. Fluid consumption and the risk of bladder cancer: results of a multicenter case–control study. Int J Cancer. 2001;93:880–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Sala M, Cordier S, Chang-Claude J, Donato F, Escolar-Pujolar A, Fernandez F, Gonzalez CA, Greiser E, Jockel KH, Lynge E, Mannetje A, Pohlabeln H, Porru S, Serra C, Tzonou A, Vineis P, Wahrendorf J, Boffetta P, Kogevina M. Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case–control studies in European countries. Cancer Causes Control. 2000;11:925–31.PubMedCrossRefGoogle Scholar
  8. 8.
    Tavani A, La Vecchia C. Coffee and cancer: a review of epidemiological studies, 1990–1999. Eur J Cancer Prev. 2000;9:241–56.PubMedCrossRefGoogle Scholar
  9. 9.
    Villanueva CM, Cantor KP, King WD, Jaakkola JJ, Cordier S, Lynch CF, Porru S, Kogevinas M. Total and specific fluid consumption as determinants of bladder cancer risk. Int J Cancer. 2006;118:2040–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Woolcott CG, King WD, Marrett LD. Coffee and tea consumption and cancers of the bladder, colon and rectum. Eur J Cancer Prev. 2002;11:137–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Zeegers MP, Dorant E, Goldbohm RA, van den Brandt PA. Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. Cancer Causes Control. 2001;12:231–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Zeegers MP, Tan FE, Goldbohm RA, van den Brandt PA. Are coffee and tea consumption associated with urinary tract cancer risk? A systematic review and meta-analysis. Int J Epidemiol. 2001;30:353–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Strange RC, Fryer AA. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. In: Vineis P, Malats N, Lang M, d’Errico A, Caporaso N, Cuzick J, Boffetta P, editors. Metabolic polymorphisms and susceptibility to cancer. Lyon: IARC Scientific publications No 148; 1999. p. 231–49.Google Scholar
  14. 14.
    Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, Gelatti U, Spaliviero M, Placidi D, Carta A, Scotto di Carlo A, Porru S. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004;110:598–604.PubMedCrossRefGoogle Scholar
  15. 15.
    Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, Lan Q, Boffetta P, Vineis P, Autrup H, Bell DA, Branch RA, Brockmöller J, Daly AK, Heckbert SR, Kalina I, Kang D, Katoh T, Lafuente A, Lin HJ, Romkes M, Taylor JA, Rothman N. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol. 2002;156:95–109.PubMedCrossRefGoogle Scholar
  16. 16.
    Sanderson S, Salanti G, Higgins J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol. 2007;166:741–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Kellen E, Hemelt M, Broberg K, Golka K, Kristensen VN, Hung RJ, Matullo G, Mittal RD, Porru S, Povey A, Schulz WA, Shen J, Buntinx F, Zeegers MP, Taioli E. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol. 2007;165:1221–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Glatt H, Engelke CE, Pabel U, Teubner W, Jones AL, Coughtrie MW, Andrae U, Falany CN, Meinl W. Sulfotransferases: genetics and role in toxicology. Toxicol Lett. 2000;112–113:341–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Vineis P, Malats N, Lang M, d’Errico A, Caporaso N, Cuzick J, Boffetta P, editors. Metabolic polymorphisms and susceptibility to cancer. Lyon: IARC Scientific publications No 148; 1999.Google Scholar
  20. 20.
    Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X. Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case–control study. Cancer Lett. 2003;202:61–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Gu J, Liang D, Wang Y, Lu C, Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res. 2005;581:97–104.PubMedGoogle Scholar
  22. 22.
    Karagas MR, Park S, Warren A, Hamilton J, Nelson HH, Mott LA, Kelsey KT. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study. Cancer Lett. 2005;219:63–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Huber WW, Parzefall W. Modification of N-acetyltransferases and glutathione S-transferases by coffee components: possible relevance for cancer risk. Methods Enzymol. 2005;401:307–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Huber WW, Rossmanith W, Grusch M, Haslinger E, Prustomersky S, Peter-Vörösmarty B, Parzefall W, Scharf G, Schulte-Hermann R. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol. 2007;25 [Epub ahead of print].Google Scholar
  25. 25.
    Porta M, Vioque J, Ayude D, Alguacil J, Jariod M, Ruiz L, Murillol JA. Coffee drinking: the rationale for treating it as a potential effect modifier of carcinogenic exposures. Eur J Epidemiol. 2003;18:289–98.PubMedCrossRefGoogle Scholar
  26. 26.
    Link CJ Jr, Evans MK, Cook JA, Muldoon R, Stevnsner T, Bohr VA. Caffeine inhibits gene-specific repair of UV-induced DNA damage in hamster cells and in human xeroderma pigmentosum group C cells. Carcinogenesis. 1995;16:1149–55.PubMedCrossRefGoogle Scholar
  27. 27.
    Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMedGoogle Scholar
  28. 28.
    Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S, Karagas M, Casetta G, Rolle L, Piazza A, Vineis P. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case–control study. Cancer Epidemiol Biomarkers Prev. 2005;14:2569–78.PubMedCrossRefGoogle Scholar
  29. 29.
    Shen M, Hung RJ, Brennan P, Malaveille C, Donato F, Placidi D, Carta A, Hautefeuille A, Boffetta P, Porru S. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case–control study in northern Italy. Cancer Epidemiol Biomarkers Prev. 2003;12:1234–40.PubMedGoogle Scholar
  30. 30.
    Hung RJ, Brennan P, Malaveille C, Porru S, Donato F, Boffetta P, Witte JS. Using hierarchical modeling in genetic association studies with multiple markers: application to a case–control study of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1013–21.PubMedGoogle Scholar
  31. 31.
    García-Closas M, Malats N, Real FX, Welch R, Kogevinas M, Chatterjee N, Pfeiffer R, Silverman D, Dosemeci M, Tardón A, Serra C, Carrato A, García-Closas R, Castaño-Vinyals G, Chanock S, Yeager M, Rothman N. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, Carta A,Hautefeuille A, Porru S. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25:973–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Porru S, Placidi D, Carta A, Gelatti U, Ribero ML, Tagger A, Boffetta P, Donato F. Primary liver cancer and occupation in men: a case–control study in high-incidence area in Northern Italy. Int J Cancer. 2001;94:878–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Donato F, Boffetta P, Fazioli R, Aulenti V, Gelatti U, Porru S. Bladder cancer, tobacco smoking, coffee and alcohol drinking in Brescia, northern Italy. Eur J Epidemiol. 1997;13:795–800.PubMedCrossRefGoogle Scholar
  35. 35.
    Pohlabeln H, Jockel KH, Bolm-Audorff U. Non-occupational risk factors for cancer of the lower urinary tract in Germany. Eur J Epidemiol. 1999;15:411–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Murta-Nascimento C, Silverman DT, Kogevinas M, García-Closas M, Rothman N, Tardón A, García-Closas R, Serra C, Carrato A, Villanueva C, Dosemeci M, Real FX, Malats N. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev. 2007;16:1595–600.PubMedCrossRefGoogle Scholar
  37. 37.
    Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Castano-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Tora M, Fernandez F, Real FX, Rothman N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366:649–59.PubMedCrossRefGoogle Scholar
  38. 38.
    Srivastava DS, Mishra DK, Mandhani A, Mittal B, Kumar A, Mittal RD. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur Urol. 2005;48:339–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, Piazza A, Vineis P. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Nehlig A, Debry G. Potential genotoxic, mutagenic and antimutagenic effects of coffee: a review. Mutat Res. 1994;317:145–62.PubMedGoogle Scholar
  41. 41.
    Majer BJ, Hofer E, Cavin C, Lhoste E, Uhl M, Glatt HR, Meinl W, Knasmuller S. Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2). Food Chem Toxicol. 2005;43:433–41.PubMedCrossRefGoogle Scholar
  42. 42.
    Okamura S, Suzuki K, Yanase M, Koizumi M, Tamura HO. The effects of coffee on conjugation reactions in human colon carcinoma cells. Biol Pharm Bull. 2005;28:271–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Donato F, Boffetta P, Fazioli R, Gelatti U, Porru S. Reliability of data on smoking habit and coffee drinking collected by personal interview in a hospital-based case–control study. Eur J Epidemiol. 1998;14:259–67.PubMedCrossRefGoogle Scholar
  44. 44.
    Schaid DJ, Jacobsen SJ. Biased tests of association: comparisons of allele frequencies when departing from Hardy–Weinberg proportions. Am J Epidemiol. 1999;149:706–11.PubMedGoogle Scholar
  45. 45.
    Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford: Blackwell Scientific Publications; 1994.Google Scholar
  46. 46.
    Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Loredana Covolo
    • 1
  • Donatella Placidi
    • 2
  • Umberto Gelatti
    • 1
  • Angela Carta
    • 2
  • Antonio Scotto Di Carlo
    • 2
  • Paolo Lodetti
    • 1
  • Antonio Piccichè
    • 1
  • Grazia Orizio
    • 1
  • Marcello Campagna
    • 2
  • Cecilia Arici
    • 2
  • Stefano Porru
    • 2
  1. 1.Department of Experimental and Applied Medicine, Institute of Hygiene, Epidemiology and Public HealthUniversity of BresciaBresciaItaly
  2. 2.Section of Occupational HealthUniversity of BresciaBresciaItaly

Personalised recommendations